John Hopkins
Denosumab, an inhibitor of RANKL, suppresses erosions but has no effect on articular signs and symptoms in rheumatoid arthritis
Tue, 27 May 2008 11:47:01 -0400
Bone erosions in response to inflammation in RA are driven by osteoclasts which are in turn activated by RANKL (Receptor Activator for Nuclear Factor κ B Ligand) binding to its receptor RANK. Inhibition of RANKL has the potential to retard bone erosions in RA patients, thereby limiting progressive joint damage and destruction.
Conquering Arthritis
There is a Cure for Arthritis
#social-bookmarks#
Denosumab, an inhibitor of RANKL, suppresses erosions but has no effect on articular signs and symptoms in rheumatoid arthritis
Tue, 27 May 2008 11:47:01 -0400
Bone erosions in response to inflammation in RA are driven by osteoclasts which are in turn activated by RANKL (Receptor Activator for Nuclear Factor κ B Ligand) binding to its receptor RANK. Inhibition of RANKL has the potential to retard bone erosions in RA patients, thereby limiting progressive joint damage and destruction.
Conquering Arthritis
There is a Cure for Arthritis
#social-bookmarks#
posted by Ajax at
7:14 AM
0 Comments:
Post a Comment
<< Home